| Jean Marie Brown Ly, MD | |
|
3570 S Tuttle Ave, Sarasota, FL 34239-6405 | |
| (941) 927-4888 | |
| Not Available |
| Full Name | Jean Marie Brown Ly |
|---|---|
| Gender | Female |
| Speciality | Allergy/immunology |
| Experience | 16 Years |
| Location | 3570 S Tuttle Ave, Sarasota, Florida |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568623551 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207K00000X | Allergy & Immunology | ME116920 (Florida) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hugh H Windom Md Pa | 1658558176 | 4 |
News Archive
More than 30 million Americans suffer from osteoarthritis of the knee, according to the Centers for Disease Control and Prevention.
Presidio Pharmaceuticals, Inc. announced today that they have selected a second clinical candidate, PPI-1301, from their hepatitis C virus (HCV) NS5A program for advancement into clinical development. Presidio's first NS5A inhibitor, PPI-461, is currently undergoing evaluation in a Phase 1a clinical study.
Researchers from Sechenov University in collaboration with colleagues from Germany, Greece and Russia reviewed scientific articles on the role of zinc in the prevention and treatment of viral infections and pneumonia, with projections on those caused by SARS-CoV-2. The results were published in the International Journal of Molecular Medicine.
Raptor Pharmaceuticals Corp. has announced that its clinical development subsidiary, Bennu Pharmaceuticals Inc. , has initiated the Company's first clinical-stage program after dosing the first cohort in a Phase IIa study of oral 4-methylpyrazole ("4-MP") in subjects with ALDH2 deficiency, or ethanol intolerance, as the initial development stage of its Convivia program.
› Verified 9 days ago
| Entity Name | Hugh H Windom Md Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962701193 PECOS PAC ID: 1658558176 Enrollment ID: O20110610000218 |
News Archive
More than 30 million Americans suffer from osteoarthritis of the knee, according to the Centers for Disease Control and Prevention.
Presidio Pharmaceuticals, Inc. announced today that they have selected a second clinical candidate, PPI-1301, from their hepatitis C virus (HCV) NS5A program for advancement into clinical development. Presidio's first NS5A inhibitor, PPI-461, is currently undergoing evaluation in a Phase 1a clinical study.
Researchers from Sechenov University in collaboration with colleagues from Germany, Greece and Russia reviewed scientific articles on the role of zinc in the prevention and treatment of viral infections and pneumonia, with projections on those caused by SARS-CoV-2. The results were published in the International Journal of Molecular Medicine.
Raptor Pharmaceuticals Corp. has announced that its clinical development subsidiary, Bennu Pharmaceuticals Inc. , has initiated the Company's first clinical-stage program after dosing the first cohort in a Phase IIa study of oral 4-methylpyrazole ("4-MP") in subjects with ALDH2 deficiency, or ethanol intolerance, as the initial development stage of its Convivia program.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jean Marie Brown Ly, MD 3570 S Tuttle Ave, Sarasota, FL 34239-6405 Ph: (941) 927-4888 | Jean Marie Brown Ly, MD 3570 S Tuttle Ave, Sarasota, FL 34239-6405 Ph: (941) 927-4888 |
News Archive
More than 30 million Americans suffer from osteoarthritis of the knee, according to the Centers for Disease Control and Prevention.
Presidio Pharmaceuticals, Inc. announced today that they have selected a second clinical candidate, PPI-1301, from their hepatitis C virus (HCV) NS5A program for advancement into clinical development. Presidio's first NS5A inhibitor, PPI-461, is currently undergoing evaluation in a Phase 1a clinical study.
Researchers from Sechenov University in collaboration with colleagues from Germany, Greece and Russia reviewed scientific articles on the role of zinc in the prevention and treatment of viral infections and pneumonia, with projections on those caused by SARS-CoV-2. The results were published in the International Journal of Molecular Medicine.
Raptor Pharmaceuticals Corp. has announced that its clinical development subsidiary, Bennu Pharmaceuticals Inc. , has initiated the Company's first clinical-stage program after dosing the first cohort in a Phase IIa study of oral 4-methylpyrazole ("4-MP") in subjects with ALDH2 deficiency, or ethanol intolerance, as the initial development stage of its Convivia program.
› Verified 9 days ago
Dr. Hugh H Windom, M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 3570 S Tuttle Ave, Sarasota, FL 34239 Phone: 941-927-4888 Fax: 941-927-5808 | |
Donna M Jamieson, M.D. Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 2650 Bahia Vista St, Ste 304, Sarasota, FL 34239 Phone: 941-366-9711 Fax: 941-957-0079 | |
Dr. Mildred Elena Pastorizo, MD Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 2200 Ringling Blvd, Sarasota, FL 34237 Phone: 941-861-2709 | |
Dr. Eva A Berkes, Allergy & Immunology Medicare: Medicare Enrolled Practice Location: 2068 Hawthorne St, Suite 202, Sarasota, FL 34239 Phone: 941-953-5050 Fax: 941-343-8021 | |
Dr. Frederick L Bloom, M.D. Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 2650 Bahia Vista St, Ste 304, Sarasota, FL 34239 Phone: 941-366-9711 Fax: 941-957-0079 | |
Dr. Sharlene J Llanes, M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 1250 S Tamiami Trl Ste 302, Sarasota, FL 34239 Phone: 941-366-9711 |